|
楼主 |
发表于 2008-11-20 14:32:32
|
显示全部楼层
119-6-第六节 硫哩漂吟的用法及注意事项
硫哩嚓吟的有效剂量为1. 5 -2 . 5mg/(kg "d)。在<1 mg/(kg " d )的剂量无治疗作用。在类风湿关节炎治疗中,本品可单用或与慢作用抗风湿药合用。但是,硫哇嗦吟单独应用对类风湿关节炎的治疗效果并不优于D一青霉胺或金制剂。其不良反应发生率与常用的慢作用抗风湿药类似。因此,硫噢嗦吟可能是类风湿关节炎联合治疗中可供选择的药物之一。
. k/ {' c* v3 v/ z) J: x3 C P8 X" C: N0 M! U: k1 B
一般而言,硫哇嚷吟第一周起始剂量为50mg/d。如能耐受,剂量可增加至2 . 5mg/(kg.d)。如以体重60kg计,每日剂量为0. 18g.用药前4周,应每2周检查血象和肝功能。如正常,以后改为每月检查一次。如果白细胞计数降至3.0 x 109/L以下,必需停药。白细胞在(3.0 4.0) x 109/L之间,则需提高监测频度,并考虑减量。减量后如血象恢复,以后也最好应用较小的剂量。减量或停药后,恶心和其他胃肠道反应常会随之好转。如有过敏反应,以后不应再考虑用硫哇嗓吟治疗。9 X. @7 l$ q7 m! |- A9 K Q! S, d' z+ {: W
4 H9 v3 K, s* h8 ~. ` 在合并别嚷醇治疗的患者,剂量应减少至1/4-1/3。在肾功能不全的患者也应根据肌醉清除率减少用药剂量。应尽量避免同时使用ACEI类药物治疗。
- N3 j4 p3 K3 g( O, G+ k
& F; a" U- Z) Q/ L r9 l( @ 孕妇最好不用本药治疗。但目前虽有导致染色体畸变和胎儿发育迟滞的报道,还未肯定其在人类有致畸作用。对必需硫噢嗦吟治疗的患者,妊娠过程中,不必强求一定停药。
6 j3 b* c7 C5 B3 b/ }1 z. p ( 穆 荣 )2 \, e' `$ o* X8 n- C
参考文献:
0 X) M4 n5 F" j6 A$ N
p0 U; P) T ?0 l: _" H 施桂英.关节炎概要.北京:中国医药科技出版社,2000.550 William J. Koopman. Arthritis and allied condition. USA.2000.794一814 1 P5 s( u+ O! R* o
1 @' Y% n/ s" ^9 p) w3 v: v Calin A. A placebo controlled, crossover study of azathio-prine in Reiter's syndrome. Ann Rheum Dis,1986-45(8):653一655 : e1 C$ W1 z9 F3 N
! M5 _, I+ n" ` K* S! h/ ]/ q
E.Choy, G. Kingsley. How do second-line agents work?British Medical Bulletin, 1995.51(2) :472一492
0 p/ P# z7 e$ y- M7 O9 [0 \/ \3 G! l; ?) j% \3 t+ v/ o3 D) n
K. Gaffney, D. G. 1. Scott. Azathioprine and cyclophos-phamide in the treatment of rheumatoid arthritis. Bri J Rheuma-tology,1998.37:824一836 : C+ L. }9 D$ Q t
) a: Y$ A6 ^# M9 [! g! g Kerstens PJ, Stolk JN, Boerbooms AM, et. al. Purine en-zymes in rheumatoid arthritis. Ann Rheum Dis,1994. 53: 608一611 " f& B& \( d8 T( E1 v
6 ]- m1 u& j; l% N Kerstens PJ, Boerbooms AM, Jeurissen ME, et al. Radio-logical and clinical results of longterm treatment of rheumatoidarthritis with methotrexate and azathioprine. J Rheumato1,200027(5):1148一1155
j# g5 T3 a3 w) X2 u
# d: F" p2 t. `& b( e8 t Papadopoulos NG, Alamanos Y, Papadopoulos IA et al.Disease modifying antirheumatic drugs in early rheumatoid arthritis: a long term observational study. J Rheumatol, 2002. 29 ( 2 ):261一266 - t0 y/ y# C! ^! w
% U2 @7 J" g$ z
Ricardo B, Victor M M T, Miguel A G G, et al. Acutefebrile toxic reaction with refractory rheumatoid arthritis who arereceiving combined therapy with MTX and AZA. ArthritisRheum, 1996. 39:1016一1020# o' x: q3 |6 c+ P- M3 ~
% c4 M; l& Z" R4 e, w* t
Rosalind R G, Ellen S. Immunosupressive drug use duringpregnancy. Rheum dis clin north Am. 1997. 23:149一1673 n# E- }) u7 l: M9 g' m) J# A1 h% t8 E- F
6 j. q0 u V- ~% y0 ]8 H* Z
Willkens RF, Sharp JT, Stablein D, et al. Comparison ofazathioprine, methotrexate, and the combination of the two inthe treatment of rheumatoid arthritis. A forty-eight-week con-trolled clinical trial with radiologic outcome assessment. ArthritisRheum, 1996.39(8):1436一1437 |
|